Kolexia
Ribeil Antoine-Jean Hématologie
Ribeil Antoine-Jean
Hématologie
Hôpital Necker Enfants Malades
Paris, France
173 Activités
786 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Drépanocytose Thalassémie Bêta-Thalassémie Anémie Hémoglobinopathies Syndromes myélodysplasiques Hémolyse Carence en vitamine D Splénomégalie

Collaborateurs

Voir plus
Arlet Jean-Benoit
Arlet Jean-Benoit
Hôpital Européen Georges Pompidou, Paris, France
Cavazzana Marina
Cavazzana Marina
Hôpital Necker Enfants Malades, Paris, France
Hermine Olivier
Hermine Olivier
Hôpital Necker Enfants Malades, Paris, France
De Montalembert Mariane
De Montalembert Mariane
Hôpital Necker Enfants Malades, Paris, France

Industries

Voir plus
KeyQuest Health Ltd.
2 collaboration(s)
Dernière en 2017
Addmedica
1 collaboration(s)
Dernière en 2017
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
A Study Evaluating the Safety and Efficacy of bb1111 in Severe Sickle Cell Disease: A Phase 1/2 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With the LentiGlobin BB305 Lentiviral Vector in Subjects With Severe Sickle Cell Disease
Essai Clinique (Bluebird)   08 février 2024
Long-term Follow-up of Subjects With Sickle Cell Disease Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector
Essai Clinique (Bluebird)   08 janvier 2024
Gene-addition/editing therapy in sickle cell disease
Presse medicale (Paris, France : 1983)   01 décembre 2023
Long-term Follow-up of Subjects With Transfusion-Dependent β-Thalassemia (TDT) Treated With Ex Vivo Gene Therapy Using Autologous Hematopoietic Stem Cells Transduced With a Lentiviral Vector
Essai Clinique (Bluebird)   13 octobre 2023
Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.: A Phase 2A, Open-label Dose Finding Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With BETA(b)-THALASSEMIA.
Essai Clinique (Celgene)   23 mai 2023
Lovo-cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB-206 study.
American journal of hematology   10 octobre 2022
A Study Evaluating the Safety and Efficacy of LentiGlobin BB305 Drug Product in β-Thalassemia Major (Also Referred to as Transfusion-dependent β-Thalassemia [TDT]) and Sickle Cell Disease: A Phase 1/2 Open Label Study Evaluating the Safety and Efficacy of Gene Therapy of the β-Hemoglobinopathies (Sickle Cell Anemia and β-Thalassemia Major) by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo With a Lentiviral β-A-T87Q Globin Vector (LentiGlobin BB305 Drug Product)
Essai Clinique (Bluebird)   05 avril 2022
Long-term outcomes of lentiviral gene therapy for the β-hemoglobinopathies: the HGB-205 trial.
Nature medicine   24 janvier 2022
Biologic and Clinical Efficacy of LentiGlobin for Sickle Cell Disease.
The New England journal of medicine   12 décembre 2021
Pregnancy outcome in women with transfused beta-thalassemia in France.
Annals of hematology   20 octobre 2021